Page 210 – F-Prime Capital

New York Startup, Quartet Health, Finds the Right Algorithm for Mental Health

February 1, 2016

Quartet Health wants to make mental health parity a reality.

Doctors have access to all sorts of historical patient records, which help them make diagnoses and referrals. Now they are gaining access to a technology platform that analyzes all of that data to learn if the patient’s physiological symptoms are likely to be associated with―and possibly exacerbated by―a simultaneous mental health condition.

In the medical world, this is called comorbidity. For New York-based startup Quartet Health, it might soon be called a goldmine.

Quartet was launched in early 2014 by Arun Gupta, who at the time was working as a healthcare-focused private equity investor. What he saw was that behavioral health issues kept coming up at some of his firm’s portfolio companies, and that the discipline was rarely being addressed by applying basic technologies. At the same time, Gupta also was serving as an advisor to Palantir Technologies, a secretive Silicon Valley company known for applying big data analytics to seemingly intractable problems.

Steward ACO Picks Quartet Health for Behavioral Health IT

January 29, 2016

Steward Health Care Network, the second largest physician network in Massachusetts, will offer Quartet Health’s platform as a service to its providers and their patients.

The multi-year agreement expands the partnership between Steward and Quartet Health that started in 2015.

Boston-based Steward Health Care, a Next Generation ACO, is the largest integrated community care organization and hospital network in New England, with more than 17,000 employees in more than 150 communities.

Former Rhode Island Congressman Patrick Kennedy joined the board of the New York-based startup last October.

Eris Launches Major Expansion of Standard Swap Futures

January 26, 2016

Eris Exchange (Eris), a U.S.-based futures exchange offering swap futures as a regulatory-compliant and capital-efficient alternative to OTC swaps, announced the expansion of its flagship Eris Standard U.S. Dollar Interest Rate Swap Future complex on January 11th . This launch follows a record year in 2015 for Eris Exchange in terms of volume, open interest, trade count, and number of participants, as well as the addition of multiple new Liquidity Providers, clearing firms, and execution platforms.

“The Eris product design is best in class – and this launch represents a quantum leap forward in terms of extending the product to a wider set of structures that capture the valuable flexibility previously only found in OTC swaps,” said John Coleman, Director of the Fixed Income Group & Senior Vice President of R.J. O’Brien & Associates. “Now mortgage hedgers can better manage risk in the 12- to 15-year points on the curve, banks can efficiently manage swap spread risk, and insurance companies can address long-dated liabilities.”

Recurly Reports Holiday Season was Exponentially Successful for Subscription Companies

January 22, 2016

This morning subscription management platform Recurly announced results of the 2015 holiday season, which was exponentially successful for subscription merchants.

The results were drawn from a sample of 450 business-to-consumer subscription-based merchants who are clients of Recurly. The study period was two weeks long from Sunday, November 22 through Saturday, December 5, 2015, which included Black Friday and Cyber Monday.

Recurly reported the following results:

On Cyber Monday, subscription-based merchants experienced a 230% jump in sales compared to other days during the study period.
Same-store sales on Cyber Monday grew 83% compared to the previous year.
From Black Friday through Cyber Monday, same-store sales grew 70% from the previous year.
Three times more coupons were redeemed on Cyber Monday compared to other days during the study period.

USHealthVest’s Chicago Behavioral Hospital launches center for veterans’ mental health

January 21, 2016

Des Plaines, Illinois, January 15, 2016 – Chicago Behavioral Hospital, owned by USHealthvest, has opened Extra Mile Veteran Care™, the first specialized private outpatient program in Cook County to be operated by military veteran health practitioners, to address the unique mental health and chemical dependency needs of veterans and their families. More than 700,000 veterans of all generations live in Illinois and more than 25 percent reside in Cook County.

The Extra Mile Veteran Care™ leadership and clinical team, primarily veterans from all foreign wars, focus on evidence-based practices to understand and address mental health and addiction needs. Numerous studies affirm that evidence-based interventions such as cognitive behavioral therapy, mentoring, motivational enhancement therapy, trauma-focused therapy and wellness programs often work best for veterans with mental health and addiction problems.

TraceLink Announces NEXUS ’16: Mastering Global Traceability with a Digital Supply Chain Network

January 20, 2016

TraceLink Inc., the world’s largest track and trace network for connecting the Life Sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace, today announced NEXUS ’16—the company’s annual gathering of business leaders and pharmaceutical supply chain professionals dedicated to shaping the future of global drug traceability for Life Sciences. The two-day event will be held on October 19 and 20, at the Revere Hotel Boston, with a special evening event at the John F. Kennedy Presidential Library & Museum. Registration for NEXUS ’16 is now open, with early purchase discounts available for all tickets sales before June 1, 2016.

Aclaris Therapeutics Initiates Phase 3 Clinical Trials Of A-101 For The Treatment Of Seborrheic Keratosis

January 19, 2016

Aclaris Therapeutics, Inc. (NASDAQ:ACRS), today announced the initiation of two Phase 3 clinical trials to evaluate A-101 Topical Solution for the treatment of seborrheic keratosis (SK).

The two Phase 3 clinical trials will evaluate the safety and efficacy of A-101 Topical Solution compared with a vehicle solution (placebo). Approximately 800 subjects will be randomized in these multi-center, double-blinded, vehicle-controlled, clinical trials, which are being conducted at 34 investigational centers within the United States.

“The initiation of the Phase 3 program for A-101 Topical Solution is an important milestone in our development program and follows the positive Phase 2 clinical results and an End-of-Phase 2 meeting with the FDA,” said Christopher Powala, Chief Operating Officer of Aclaris. “Our goal is to offer a new treatment option for patients and physicians to treat SK lesions, a condition for which there are currently no FDA-approved drugs.”

TraceLink Boosts Leadership Position as Proven Track and Trace Network Exceeds 200,000

January 14, 2016

TraceLink Inc., the world’s largest track and trace network for connecting the Life Sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace, today announced that its Life Sciences Cloud has exceeded more than 200,000 connected members across the global pharmaceutical supply chain. A single connection to the Life Sciences Cloud allows pharmaceutical manufacturers, CMOs, distributors and dispensers of any size to connect with any trading partner that is already configured on the network and instantly begin sharing documents and data for regulatory compliance. In addition, the company’s 15 commercially available drug traceability solutions are now used by pharmaceutical suppliers in global markets that comprise 75 percent of the world’s drug supply.

“The unique approach we’ve taken with our network model is what sets TraceLink apart, and continues to fuel our success,” said Shabbir Dahod, president and CEO of TraceLink. “Other vendors suggest that on premise systems and single-tenant architectures can address the complex compliance challenges facing the industry, but the reality is that these approaches just can’t scale to meet the serialization processing and data exchange demands of the new regulatory laws. Our track and trace network is proven to accelerate the ability for any pharmaceutical manufacturer, distributor or dispenser to achieve regulatory compliance with the least cost, time and risk—which is why we’ve been able to grow our network from a few thousand suppliers to more than 200,000 in a little over a year.”

In specialized cross-border payments space, Flywire expands from universities to hospitals

January 14, 2016

Started as a way to help university students drastically reduce fees associated with cross-border tuition payments, Flywire began partnering with hospitals last year to extend its business model to international patients. The expansion is a sign of both the growth of cross-border payments, and the growing number of choices targeting the parties making those payments.

The cross-border payments space, estimated to be $300 billion at the end of 2015, has become increasingly competitive in recent years. The number of companies eyeing cross-border payments as a corner of banking where technology can slash traditional costs, prompted PYMNTS.com to begin tracking 192 cross-border payments companies last year, through its X-Border Payments Optimization Index, powered by Digital River World Payments. Many of those companies are highly specialized, focusing on subsets of the cross-border payment industry ranging from remittances to large international business to business transactions.

Trivitron patents NeoMass AAAC kit for newborn screening to detect 50 inborn disorders

January 12, 2016

Trivitron Healthcare has launched NeoMass AAAC Kit (CE Approved) for expanded panel of newborn screening in India. This is the first kit in the global market that can detect up to 50 disorders that a newborn baby might be born with or without any immediate symptoms or visible manifestations, making it the broadest available panel of biomarkers. The launch of NeoMass AAAC Kit makes Trivitron a complete solution provider for NBS with modular systems, automated systems and kits for core panel screening and Tandem MS/ MS and NeoMass AAAC kit for expanded panel screening. Dr Ralph Fingerhut, Director Swiss Newborn Screening Laboratory University Children’s Hospital, Zurich and Nitin Sawant, Sr VP, Trivitron Healthcare announced the launch of NeoMass AAAC Kit patented by Trivitron in India and shared insights about newborn screening, its causes, global and Indian scenario, importance, facts and figures etc.

Blog